Overview
Mermaid diagram (expand to render)
NCT06597058 is a double-blind, placebo-controlled Phase 2 estimation study evaluating the efficacy and safety of a fixed-dose combination polypill (MAR Active 0.6g tablet) in subjects with Alzheimer's Disease. Sponsored by Noah Pharmaceuticals, Inc., the trial enrolled 103 participants and is designed to estimate treatment effect across multiple cognitive and functional endpoints["@nct06597058"].
The MAR polypill represents a multi-target, combination therapy approach to Alzheimer's disease — combining multiple pharmacological agents in a single tablet to address the multifactorial pathophysiology of AD. This strategy differs from single-target monoclonal antibody approaches (like [lecanemab](/clinical-trials/lecanemab-phase-3) or [donanemab](/clinical-trials/donanemab-trailblazer-alz2)) by targeting multiple disease pathways simultaneously through synergistic drug combinations["@polypill_concept"].
The polypill approach is grounded in the understanding that Alzheimer's disease involves multiple interconnected pathophysiological mechanisms — including amyloid accumulation, tau pathology, neurotransmitter deficits, neuroinflammation, and metabolic dysfunction — and that addressing these simultaneously may produce greater clinical benefit than targeting a single pathway["@ad_polypill_history"].
| Field | Value |
|-------|-------|
| NCT Number | NCT06597058 |
| Title | A Double-Blind, Placebo-Controlled Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill Administered to Subjects With Alzheimer's Disease |
| Phase | Phase 2 |
| Status | Recruiting / Active |
| Sponsor | Noah Pharmaceuticals, Inc. |
| Intervention | MAR Active 0.6g tablet (experimental) vs MAR Placebo 0.6g tablet |
| Participants | 103 (estimated) |
| Age Range | 50-85 years |
| Condition | Alzheimer's Disease (very mild to severe) |
| Study Design | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled, parallel-group |
| Start Date | October 16, 2024 |
| Primary Completion | December 31, 2025 (estimated) |
| Study Completion | February 15, 2026 (estimated) |
Scientific Rationale
The Polypill Concept in Neurodegeneration
The polypill strategy — combining multiple approved drugs in a single formulation — originated in cardiovascular medicine, where fixed-dose combination pills have demonstrated significant improvements in adherence and outcomes for hypertension, dyslipidemia, and secondary prevention[@polypill_cardiovascular]. The translation of this approach to Alzheimer's disease reflects growing recognition that AD is a multifactorial disease requiring multi-target intervention[@multifactorial_ad].
Key Rationale for the Polypill Approach in AD:
Pathway Complexity: AD involves simultaneous dysfunction across amyloid processing, tau phosphorylation, cholinergic transmission, glutamate excitotoxicity, neuroinflammation, oxidative stress, and metabolic deficits — no single drug can address all these targets effectively.
Synergistic Effects: Fixed-dose combinations allow multiple agents to work synergistically, potentially amplifying therapeutic benefit while maintaining tolerability.
Improved Adherence: A single pill simplifies the medication regimen for patients with cognitive impairment, reducing the burden on caregivers and improving compliance with multi-drug regimens.
Repurposing Advantage: The polypill can combine established generic medications with proven safety profiles, potentially reducing development timelines and costs compared to novel single-target agents.
Individualized Components: While delivered as a single pill, each component targets a distinct pathway — enabling a broader therapeutic reach than any single agent.Comparison with Other AD Therapeutic Approaches
| Approach | Examples | Mechanism | Advantages | Limitations |
|----------|----------|-----------|------------|-------------|
| Anti-amyloid mAbs | Lecanemab, Donanemab | Remove amyloid plaques | Disease-modifying, biomarker evidence | ARIA risk, IV administration, cost |
| Cholinesterase inhibitors | Donepezil, Rivastigmine | Boost acetylcholine | Oral, well-established | Symptomatic only |
| Polypill/Multi-target | MAR (NCT06597058) | Multiple pathways | Synergistic, oral, repurposed agents | Unproven in AD, complexity |
| Symptomatic agents | Memantine, Exelon | Various | Symptomatic benefit | Do not modify disease |
Noah Pharmaceuticals
Noah Pharmaceuticals, Inc. is a pharmaceutical company focused on the development of combination therapies for neurological disorders[@noah_pharma]. The MAR polypill represents their approach to Alzheimer's disease through multi-target combination therapy, leveraging the synergistic potential of multiple established agents.
The company's focus on fixed-dose combinations aligns with broader trends in CNS drug development emphasizing polypharmacology and pathway crosstalk[@fixed_dose_combo].
Trial Design
Phase 2 Estimation Study
This is a Phase 2 estimation study — designed to estimate the magnitude of treatment effect across multiple endpoints, not to definitively establish efficacy. Phase 2 estimation studies typically inform Phase 3 sample size calculations and confirmatory trial design.
The triple-blind design (participant, care provider, and investigator blinded) represents a particularly rigorous blinding approach, minimizing bias in both subjective endpoint assessments and objective measures.
Study Structure
Randomization (1:1)
|
+---> MAR Active 0.6g tablet (QD or as directed)
| |
| v
| Double-blind treatment period
| |
+---> MAR Placebo 0.6g tablet
|
v
Placebo-controlled observation
Inclusion Criteria (Expected)
Based on the trial design and endpoints, expected inclusion criteria include:
- Age: 50-85 years
- Diagnosis: Very mild to severe Alzheimer's Disease (clinical diagnosis)
- CDR-SB: ≥ 3.0 (Clinical Dementia Rating — Sum of Boxes)
- MMSE-2: 8-24 (Mini-Mental State Examination, 2nd Edition)
- Stable medications: Concomitant AD medications (cholinesterase inhibitors, memantine) must be stable
- Caregiver availability: Study requires informant/caregiver participation
Exclusion Criteria (Expected)
- Significant neurological conditions other than AD
- Major psychiatric disorders (depression, bipolar, schizophrenia)
- Recent stroke or cerebrovascular events
- Contraindications to any polypill component
- Participation in other clinical trials
Endpoints
Primary Endpoints
The trial uses a multi-domain endpoint approach assessing cognitive, functional, and global measures[@nct06597058]:
| Endpoint | Instrument | Description |
|----------|------------|-------------|
| CDR-GS | Clinical Dementia Rating — Global Score | Global dementia severity |
| CDR-SB | Clinical Dementia Rating — Sum of Boxes | Sum of 6 domain scores (0-18 scale) |
| MMSE-2 | Mini-Mental State Examination 2nd Edition | Global cognitive function (0-30) |
| ADAS-COG | Alzheimer's Disease Assessment Scale — Cognitive Subscale | Standardized cognitive assessment |
| ADCS-ADL | Alzheimer's Disease Cooperative Study — ADL | Daily living activities |
| CGI-I | Clinical Global Impressions — Improvement | Investigator-rated global improvement |
| CGI-S | Clinical Global Impressions — Severity | Investigator-rated global severity |
Safety Endpoints
| Endpoint | Monitoring |
|----------|------------|
| TEAEs | Treatment-emergent adverse events |
| SAEs | Serious adverse events |
| AEs | General adverse event monitoring |
Clinical Outcome Measures
Clinical Dementia Rating (CDR)
The CDR is a standardized instrument assessing six domains of cognitive and functional performance:
Memory
Orientation
Judgment and problem solving
Community affairs
Home and hobbies
Personal careThe CDR-GS provides an overall staging score (0 = normal, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe), while the CDR-SB provides a continuous measure sensitive to change in early stages.
MMSE-2
The Mini-Mental State Examination, Second Edition is a brief 30-point screening test assessing:
- Orientation (time and place)
- Registration
- Attention and calculation
- Recall
- Language
- Visual construction
A score range of 8-24 reflects moderate to severe cognitive impairment.
ADAS-COG
The ADAS-COG is the gold-standard cognitive outcome measure in AD clinical trials, assessing:
- Word recall
- Naming objects and fingers
- Following commands
- Constructional praxis
- Ideational praxis
- Orientation
- Word recognition
- Remembering test instructions
Higher scores indicate greater impairment.
ADCS-ADL
The ADCS-ADL assesses functional abilities through caregiver/informant report, covering:
- Basic activities (eating, dressing, bathing)
- Instrumental activities (shopping, cooking, managing finances)
- Communication abilities
Polypill Mechanism
Fixed-Dose Combination Strategy
The MAR polypill is formulated as a 0.6g tablet containing multiple active pharmaceutical ingredients in a fixed-dose combination. The specific drug combination is proprietary, but polypill strategies for Alzheimer's disease typically include agents targeting:
1. Neurotransmitter Enhancement
- Acetylcholinesterase inhibitors: Enhance cholinergic transmission by inhibiting acetylcholinesterase (similar to [donepezil](/therapeutics/donepezil-aricept), [rivastigmine](/therapeutics/rivastigmine-exelon)))
- Glutamate modulation: NMDA receptor modulation (similar to [memantine](/therapeutics/memantine))
- Antihypertensives: Address vascular contributions to cognitive decline
- Statins: Lipid-lowering with potential neuroprotective effects
- Antidiabetic agents: Address insulin resistance in AD (see [GLP-1 agonists in AD](/therapeutics/glp-1-receptor-agonists-neurodegeneration))
3. Neuroprotection
- Antioxidants: Free radical scavenging (similar to [vitamin E](/therapeutics/vitamin-e-parkinsons))
- Anti-inflammatory agents: Modulating neuroinflammation
Multi-Target Synergy
The combination of multiple agents in a single pill enables:
- Synergistic targeting: Different pathways addressed simultaneously
- Dose optimization: Each component at effective but tolerable doses
- Adherence improvement: Single pill vs. multiple medications
- Broad-spectrum coverage: More comprehensive disease modification
Alzheimer's Disease Background
Disease Overview
Alzheimer's Disease is the most common cause of dementia, affecting an estimated 6.7 million Americans aged 65 and older[@ad_epidemiology]. The disease is characterized by:
- Extracellular amyloid plaques: Accumulation of amyloid-beta (Aβ) peptides derived from [amyloid precursor protein (APP)](/genes/app) processing
- Intracellular neurofibrillary tangles: Aggregates of hyperphosphorylated [tau protein](/proteins/mapt-protein)
- Progressive neuronal loss: Particularly in hippocampus, entorhinal cortex, and association cortices
- Neuroinflammation: Microglial activation and astrocyte reactivity
- Synaptic dysfunction: Early loss of synapses correlating with cognitive decline
Treatment Landscape
The current AD treatment landscape includes:
Symptomatic therapies:
- [Acetylcholinesterase inhibitors](/therapeutics/cholinesterase-inhibitors-alzheimers) (donepezil, rivastigmine, galantamine)
- [NMDA receptor antagonists](/therapeutics/memantine) (memantine)
Disease-modifying therapies:
- [Anti-amyloid monoclonal antibodies](/therapeutics/anti-amyloid-antibodies) (lecanemab, donanemab)
Combination therapy rationale:
The rationale for multi-target approaches like the MAR polypill is strong given the modest efficacy of single-target agents and the complex, multifactorial nature of AD pathophysiology[@combination_therapy_ad].
Expected Outcomes
Potential Scenarios
Positive signals:
- Statistically significant separation from placebo on multiple cognitive endpoints
- Dose-response relationship evident
- Favorable safety profile supporting continued development
- Biomarker trends suggesting disease modification
Challenges:
- Small sample size (103) may limit statistical power
- Heterogeneity of AD patient population
- Confounding by background medications
- Regulatory pathway for fixed-dose combinations
Clinical Implications
If the MAR polypill demonstrates efficacy:
Accessibility: Oral, affordable combination therapy could democratize AD treatment
Adherence: Single-pill regimen addresses a major challenge in cognitively impaired populations
Multi-target approach: Addresses the polygenic, multifactorial nature of AD
Regulatory pathway: Fixed-dose combinations have established regulatory precedentsCross-References
Related Mechanism Pages
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology-alzheimers)
- [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation-alzheimers)
- [Neurotransmission in Alzheimer's Disease](/mechanisms/neurotransmission-alzheimers)
- [Cholinergic System Deficits](/mechanisms/cholinergic-deficits-alzheimers)
Related Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Alzheimer's Disease Clinical Trials](/diseases/alzheimers-disease-clinical-trials)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
Related Treatment Pages
- [Donepezil (Aricept)](/therapeutics/donepezil-aricept)
- [Memantine](/therapeutics/memantine)
- [Combination Therapy Approaches](/therapeutics/combination-therapy-alzheimers)
- [Anti-Amyloid Antibodies](/therapeutics/anti-amyloid-antibodies)
Related Trial Pages
- [Lecanemab Phase 3 CLARITY-AD](/clinical-trials/lecanemab-phase-3)
- [Donanemab Trailblazer-ALZ 2](/clinical-trials/donanemab-trailblazer-alz2)
- [AMDX-2011P Phase 2 AD](/clinical-trials/amdx-2011p-alzheimers-phase-2)
- [Semaglutide EVOKE Plus AD (NCT04777409)](/clinical-trials/semaglutide-evoke-plus-ad-nct04777409)
- [MK-1167 Phase 2 AD (NCT06721156)](/clinical-trials/mk-1167-merck-phase-2-ad-nct06721156)
See Also
Therapeutic Strategies
- [Disease-Modifying Therapies for AD](/therapeutics/disease-modifying-therapies)
- [Symptomatic Treatments for AD](/therapeutics/symptomatic-treatments)
- [Prevention and Risk Reduction](/therapeutics/prevention-risk-reduction)
Research Resources
- [Alzheimer's Association](https://www.alz.org)
- [Alzheimer's Therapeutic Research Institute](https://www.alzheimerstrials.org)
- [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597058)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
External Links
- [ClinicalTrials.gov: NCT06597058](https://clinicaltrials.gov/study/NCT06597058)
- [Noah Pharmaceuticals](https://noahpharmaceuticals.com)
- [Alzheimer's Association](https://www.alz.org)
- [Alzheimer's Disease Facts and Figures](https://www.alz.org/alzheimers-dementia/facts-figures)
References
[ClinicalTrials.gov: NCT06597058 — MAR Polypill Phase 2 Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06597058)
[The polypill concept: a platform for cardiovascular disease and neurodegeneration prevention (Nature Reviews Cardiology, 2023)](https://doi.org/10.1038/s41569-023-00899-5)
[The AD polypill: progress and perspectives in Alzheimer's disease prevention (Alzheimer's & Dementia, 2022)](https://doi.org/10.1016/j.jalz.2022.01.005)
[Cardiovascular polypill for secondary prevention (The Lancet, 2023)](https://doi.org/10.1016/S0140-6736(23)00256-5)
[Combination therapy approaches for Alzheimer's disease (Lancet Neurology, 2022)](https://pubmed.ncbi.nlm.nih.gov/35486931/)
[Multifactorial nature of Alzheimer's disease pathophysiology (Nature Neuroscience, 2023)](https://doi.org/10.1038/s41593-023-01285-7)
[Noah Pharmaceuticals Inc.](https://noahpharmaceuticals.com)
[Fixed-dose combination drugs in CNS disorders (Expert Opinion on Pharmacotherapy, 2023)](https://doi.org/10.1080/14656566.2023.2198765)
[Alzheimer's disease facts and figures (Alzheimer's & Dementia, 2024)](https://www.alz.org/alzheimers-dementia/facts-figures)